

# Pablo Fernandez Penas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9518448/publications.pdf>

Version: 2024-02-01

200  
papers

6,298  
citations

81900  
39  
h-index

79698  
73  
g-index

207  
all docs

207  
docs citations

207  
times ranked

6010  
citing authors

#	ARTICLE	IF	CITATIONS
1	¿Cuánta carga asistencial suponen las infecciones de transmisión predominantemente sexual y otras dermatosis anogenitales en las consultas de Dermatología en España? Resultados del muestreo aleatorio nacional DIADERM. Actas Dermo-sifiliográficas, 2022, 113, 22-29.	0.4	6
2	Dermatology inpatient consultations in a tertiary hospital – a retrospective analysis. International Journal of Dermatology, 2022, 61, 48-53.	1.0	9
3	Toxic epidermal necrolysis-like lupus erythematosus: a condition to exclude in all patients with possible Stevens-Johnson syndrome/toxic epidermal necrolysis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
4	[Translated article] What Proportion of the Spanish Dermatology Caseload Corresponds to Primarily Sexually Transmitted Infections and Other Anogenital Dermatoses? Results From the DIADERM National Random Survey. Actas Dermo-sifiliográficas, 2022, 113, T22-T29.	0.4	1
5	Management of genital hidradenitis suppurativa and lymphoedema with the restoration of erectile function. Australasian Journal of Dermatology, 2022, , .	0.7	0
6	Merkel cell carcinoma in situ: A systematic review of prognosis and management. Australasian Journal of Dermatology, 2022, 63, .	0.7	4
7	Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry ( <sc>MelCOR</sc> ): A modified Delphi study. Australasian Journal of Dermatology, 2022, , .	0.7	2
8	Cost-effectiveness of targeted genomic risk provision to prevent skin cancer: Results of a randomized trial.. Journal of Clinical Oncology, 2022, 40, 10536-10536.	1.6	0
9	Successful treatment of highly refractory necrobiotic xanthogranuloma with peginterferon alfa-2a. Clinical and Experimental Dermatology, 2021, 46, 731-733.	1.3	2
10	Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines†. Annals of Oncology, 2021, 32, 157-170.	1.2	65
11	Reflectance confocal microscopy role in mycosis fungoides follow-up. Skin Research and Technology, 2021, 27, 414-421.	1.6	3
12	Prevalence of skin examination behaviours among Australians over time. Cancer Epidemiology, 2021, 70, 101874.	1.9	11
13	¿Cuánta carga asistencial supone la enfermedad tumoral cutánea en la actividad ambulatoria en la Dermatología española? Resultados del muestreo aleatorio nacional DIADERM. Actas Dermo-sifiliográficas, 2021, 112, 632-639.	0.4	3
14	Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies. Dermatology and Therapy, 2021, 11, 971-982.	3.0	17
15	Efficiency of Detecting New Primary Melanoma Among Individuals Treated in a High-risk Clinic for Skin Surveillance. JAMA Dermatology, 2021, 157, 521.	4.1	25
16	Mass spectrometry-based proteomic analysis of the effect of storage temperature on non-invasively collected samples of human stratum corneum. Proteomics - Clinical Applications, 2021, 15, 2100005.	1.6	3
17	Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7. Dermatology and Therapy, 2021, 11, 1599-1611.	3.0	16
18	Uncovering the unmet needs among psoriasis patients in the Asia-Pacific region. Journal of Dermatology, 2021, 48, 1665-1674.	1.2	9

#	ARTICLE	IF	CITATIONS
19	Specialised skin cancer spectral library for use in data-independent mass spectrometry. <i>Proteomics</i> , 2021, 21, e2100128.	2.2	3
20	Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2149-2153.	2.4	14
21	Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1949-1956.	2.4	10
22	Adherence to suggestions after dermatology consultation in a tertiary hospital – a retrospective analysis. <i>Australasian Journal of Dermatology</i> , 2021, 62, e582-e585.	0.7	1
23	Association Between Melanoma Detected During Routine Skin Checks and Mortality. <i>JAMA Dermatology</i> , 2021, 157, 1425.	4.1	27
24	Risk Perception Plays Minimal Role in Sun Exposure Behaviours. <i>Journal of Cancer Education</i> , 2020, 35, 125-130.	1.3	1
25	Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 311-316.	1.2	55
26	Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e21-e24.	2.4	5
27	Data Independent Acquisition Proteomic Analysis Can Discriminate between Actinic Keratosis, Bowen's Disease, and Cutaneous Squamous Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 212-222.e11.	0.7	22
28	Increased collaboration between Mohs and plastic surgeons in the surgical management of skin cancer in Australia. <i>Australasian Journal of Dermatology</i> , 2020, 61, 85-87.	0.7	0
29	Systematic review and proposal of an in vivo reflectance confocal microscopy assessment tool for cutaneous lymphoma. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 295-304.	1.3	9
30	Mohs Micrographic Surgery at the Skin and Cancer Foundation Australia, 20 Years Later (1997–2017). <i>Dermatologic Surgery</i> , 2020, 46, 165-168.	0.8	4
31	Investigating proteome changes between primary and metastatic cutaneous squamous cell carcinoma using SWATH mass spectrometry. <i>Journal of Dermatological Science</i> , 2020, 99, 119-127.	1.9	9
32	Mohs Micrographic Surgery in Patients Younger Than 40 Years. <i>Dermatologic Surgery</i> , 2020, 46, 1481-1485.	0.8	0
33	Reflectance confocal microscopy as a new diagnostic tool in transformed mycosis fungoides. <i>Australasian Journal of Dermatology</i> , 2020, 61, e358-e363.	0.7	4
34	Widespread nodules and papules in a patient with chronic myelomonocytic leukemia. <i>International Journal of Dermatology</i> , 2020, 59, 1071-1072.	1.0	0
35	Allergic Contact Dermatitis of the Anogenital Region in Men and Women. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 221-224.	1.9	5
36	<p></p>A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia<p></p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 1177-1189.	4.3	21

#	ARTICLE	IF	CITATIONS
37	Proteomics: An emerging approach for the diagnosis and classification of cutaneous squamous cell carcinoma and its precursors. <i>Journal of Dermatological Science</i> , 2020, 99, 9-16.	1.9	10
38	799â€¦Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma: KEYNOTE 695 interim data. , 2020, , .		2
39	Do Dermatologic Diagnosis Change in Hot vs Cold Periods of The Year? A Sub-Analysis of the DIADERM National Sample (Spain 2016). <i>Actas Dermo-sifiliogr�ficas</i> , 2019, 110, 734-743.	0.4	0
40	Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma. <i>Melanoma Research</i> , 2019, 29, 172-177.	1.2	15
41	Management of cutaneous T�cell lymphomas: Established and emergent therapies. <i>Australasian Journal of Dermatology</i> , 2019, 60, 200-208.	0.7	3
42	Public body consciousness is associated with positive tanning attitudes and behaviours regardless of gender or age. <i>Australasian Journal of Dermatology</i> , 2019, 60, 250-251.	0.7	2
43	Keratinocyte carcinoma as a chronic disease in Australia and Spain: The importance of avoidance of perceived visible scars. <i>Australasian Journal of Dermatology</i> , 2019, 60, 284-287.	0.7	3
44	Neurocognitive Function and Quality of Life Outcomes in the ONTRAC Study for Skin Cancer Chemoprevention by Nicotinamide. <i>Geriatrics (Switzerland)</i> , 2019, 4, 31.	1.7	3
45	Incidence of cardiovascular events among tildrakizumab-treated patients with moderate to severe plaque psoriasis: Pooled data from 3 large randomized clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, AB79.	1.2	0
46	Patch Testing for Cheilitis: A 10-Year Series. <i>Dermatitis</i> , 2019, 30, 347-351.	1.6	11
47	Use of immortal time within survival analysis. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, e17.	1.2	1
48	Vitiligo�like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers. <i>Clinical and Experimental Dermatology</i> , 2019, 44, 643-646.	1.3	36
49	Derivaci�n de pacientes en consulta de dermatolog�a y de teledermatolog�a en Espa�a. Estudio DIADERM. <i>Actas Dermo-sifiliogr�ficas</i> , 2019, 110, 146-152.	0.4	13
50	Tape Stripped Stratum Corneum Samples Prove to be Suitable for Comprehensive Proteomic Investigation of Actinic Keratosis. <i>Proteomics - Clinical Applications</i> , 2019, 13, 1800084.	1.6	10
51	Tanning, selfies and social media. <i>Australasian Journal of Dermatology</i> , 2019, 60, 82-84.	0.7	2
52	An�lisis de la proporci�n de derivaciones potencialmente evitables desde Atenci�n Primaria a Dermatolog�a por lesiones qu�sticas o tumorales benignas en Espa�a. Datos del estudio DIADERM. <i>Actas Dermo-sifiliogr�ficas</i> , 2019, 110, 659-665.	0.4	9
53	�Existe variaci�n en los diagn�sticos dermatol�gicos entre la temporada de fr�o vs. calor? Un suban�lisis del estudio DIADERM (Espa�a 2016). <i>Actas Dermo-sifiliogr�ficas</i> , 2019, 110, 734-743.	0.4	7
54	The efficacy and safety of methotrexate versus interferon in cutaneous T-cell lymphomas. <i>Journal of Dermatological Treatment</i> , 2018, 29, 715-719.	2.2	4

#	ARTICLE	IF	CITATIONS
55	Is it worthy to treat hidradenitis suppurativa with adalimumab in patients with melanoma and other debilitating systemic diseases? A series of clinical dilemmas. Australasian Journal of Dermatology, 2018, 59, e297-e298.	0.7	3
56	Pigmentary evolution with pembrolizumab use. British Journal of Dermatology, 2018, 178, 32-33.	1.5	0
57	Cutaneous non-tuberculous mycobacteria in Western Sydney, Australia. Population study 1996-2013. Australasian Journal of Dermatology, 2018, 59, 343-345.	0.7	2
58	Differential proteomic analysis of actinic keratosis, Bowen's disease and cutaneous squamous cell carcinoma by label-free LC-MS/MS. Journal of Dermatological Science, 2018, 91, 69-78.	1.9	26
59	Análisis de los diagnósticos realizados en la actividad ambulatoria dermatológica en España: muestreo aleatorio nacional DIADERM. Actas Dermo-sifiliográficas, 2018, 109, 416-423.	0.4	33
60	Scar outcomes in dermatological surgery. Australasian Journal of Dermatology, 2018, 59, 48-51.	0.7	7
61	Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II. British Journal of Dermatology, 2018, 178, 715-721.	1.5	33
62	Epidermal growth factor receptor inhibitor-induced papulopustular eruption successfully treated with low-dose oral dapsone. Australasian Journal of Dermatology, 2018, 59, e219-e220.	0.7	6
63	Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab). Current Problems in Dermatology, 2018, 53, 82-92.	0.7	22
64	Naevus lightening in melanoma patients under <scp>BRAF</scp>/<scp>MEK</scp> inhibitor combination therapy versus checkpoint immunotherapy: A histological and immunohistochemistry analysis. Pigment Cell and Melanoma Research, 2018, 31, 341-344.	3.3	1
65	Atypical fibroxanthoma management: Recurrence, metastasis and disease-specific death. Australasian Journal of Dermatology, 2018, 59, 10-25.	0.7	26
66	Problemas de la CIE-10 para la codificación de diagnósticos dermatológicos. Estudio DIADERM. Actas Dermo-sifiliográficas, 2018, 109, 893-899.	0.4	5
67	Anti-programmed cell death-1 therapy-associated bullous disorders: a systematic review of the literature. Melanoma Research, 2018, 28, 491-501.	1.2	19
68	Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study. Journal of the American Academy of Dermatology, 2018, 79, 824-830.e2.	1.2	55
69	Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma. Journal of Immunotherapy, 2018, 41, 343-349.	2.4	9
70	Outpatient Dermatological Diagnoses in Spain: Results From the National DIADERM Random Sampling Project. Actas Dermo-sifiliográficas, 2018, 109, 416-423.	0.4	8
71	Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2200-2207.	2.4	42
72	Factors affecting choice of repair in Mohs micrographic surgery for non-melanoma skin cancer of the head. Australasian Journal of Dermatology, 2017, 58, 189-193.	0.7	8

#	ARTICLE	IF	CITATIONS
73	Sun Exposure Habits and Sun Protection Practices of Skaters. <i>Journal of Cancer Education</i> , 2017, 32, 734-739.	1.3	23
74	The microbiome and atopic eczema: More than skin deep. <i>Australasian Journal of Dermatology</i> , 2017, 58, 18-24.	0.7	46
75	Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, 6-16.	0.4	14
76	Experience of skin cancer and contact with health professionals is associated with increased skin cancer knowledge, but not sun safety knowledge or behaviour. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e338-e340.	2.4	3
77	Cutaneous Nodules in the Genital Area in a Patient With Chronic Graft-vs-Host Disease. <i>JAMA Dermatology</i> , 2017, 153, 465.	4.1	1
78	Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab. <i>American Journal of Dermatopathology</i> , 2017, 39, 23-27.	0.6	28
79	Drug reaction with eosinophilia and systemic symptoms in metastatic basal cell carcinoma treated with vismodegib. <i>Australasian Journal of Dermatology</i> , 2017, 58, 69-70.	0.7	10
80	Self-directed tablet education session improves safety knowledge among patients undergoing phototherapy. <i>British Journal of Dermatology</i> , 2017, 176, 1382-1384.	1.5	4
81	Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study. <i>Australasian Journal of Dermatology</i> , 2017, 58, 292-298.	0.7	9
82	PD-1 inhibitor-associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation—Report of 4 cases. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 851-856.	1.3	21
83	Systemic and erythrodermic reactions following repeated exposure to bites from the Common bed bug <i>Cimex lectularius</i> (Hemiptera: Cimicidae). <i>Austral Entomology</i> , 2017, 56, 345-347.	1.4	13
84	Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, 6-16.	0.4	31
85	Why do young adults tan?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e259-e261.	2.4	6
86	Objective severity does not capture the impact of rosacea, acne scarring and photoaging in patients seeking laser therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 361-366.	2.4	16
87	Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors). <i>Medical Journal of Australia</i> , 2017, 206, 412-412.	1.7	5
88	Acute Truncal Lymphedema Secondary to Axillary Metastatic Melanoma Presenting Like Cellulitis. <i>Case Reports in Medicine</i> , 2017, 2017, 1-3.	0.7	2
89	Management of the cutaneous adverse effects of antimelanoma therapy. <i>Melanoma Management</i> , 2017, 4, 187-202.	0.5	5
90	Cutaneous Side Effects of Single Versus Combined BRAF Inhibitors: A Comment to Erfan et al.. <i>Acta Dermato-Venereologica</i> , 2017, 97, 1267-1268.	1.3	0

#	ARTICLE	IF	CITATIONS
91	Intracorneal pustular drug eruption, a novel cutaneous adverse event in anti-programmed cell death-1 patients that highlights the effect of anti-programmed cell death-1 in neutrophils. <i>Melanoma Research</i> , 2017, 27, 641-644.	1.2	14
92	Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2016, 39, 149-152.	2.4	104
93	Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. <i>Melanoma Research</i> , 2016, 26, 413-416.	1.2	75
94	Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma. <i>Melanoma Research</i> , 2016, 26, 417-420.	1.2	37
95	PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases. <i>Melanoma Research</i> , 2016, 26, 421-424.	1.2	40
96	Direct Cost-Analysis of Mohs Micrographic Surgery and Traditional Excision for Basal Cell Carcinoma at Initial Margin Clearance. <i>Dermatologic Surgery</i> , 2016, 42, 633-638.	0.8	19
97	Treatment-specific utility weightings are needed for cost-utility analysis in metastatic melanoma. <i>British Journal of Dermatology</i> , 2016, 174, 462-463.	1.5	4
98	Transient acantholytic dyskeratosis (Grover's disease) after bone marrow transplantation. <i>Australasian Journal of Dermatology</i> , 2016, 57, e120-e122.	0.7	4
99	Classification of high risk basal cell carcinoma subtypes: experience of the ONTRAC study with proposed definitions and guidelines for pathological reporting. <i>Pathology</i> , 2016, 48, 395-397.	0.6	15
100	Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in Australia. <i>Australasian Journal of Dermatology</i> , 2016, 57, 167-174.	0.7	53
101	Mechanisms of BRAF-induced hyperproliferative cutaneous conditions. <i>Experimental Dermatology</i> , 2016, 25, 394-395.	2.9	7
102	Nicotinamide: New Indications in Dermatology. <i>Actas Dermo-sifiliográficas</i> , 2016, 107, 777-778.	0.4	2
103	FR - Nuevas indicaciones de nicotinamida en dermatología. <i>Actas Dermo-sifiliográficas</i> , 2016, 107, 777-778.	0.4	4
104	Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 455-461.e1.	1.2	247
105	Treatment of face and scalp solar (actinic) keratosis with daylight-mediated photodynamic therapy is possible throughout the year in Australia: Evidence from a clinical and meteorological study. <i>Australasian Journal of Dermatology</i> , 2016, 57, 24-28.	0.7	27
106	In Silico Analysis Validates Proteomic Findings of Formalin-fixed Paraffin Embedded Cutaneous Squamous Cell Carcinoma Tissue. <i>Cancer Genomics and Proteomics</i> , 2016, 13, 453-466.	2.0	15
107	Frequency of undiagnosed psoriatic arthritis among psoriasis patients in Australian dermatology practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2184-2191.	2.4	24
108	A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. <i>Melanoma Research</i> , 2015, 25, 265-268.	1.2	116



#	ARTICLE	IF	CITATIONS
109	Tinea hidden by a vemurafenib-induced phototoxic reaction in a patient with metastatic melanoma taking dexamethasone. Medical Journal of Australia, 2015, 203, 41-42.	1.7	4
110	Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma. Melanoma Research, 2015, 25, 91-94.	1.2	22
111	Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. Journal of the American Academy of Dermatology, 2015, 72, 809-815.e1.	1.2	39
112	Time-Dependent Measurement of Adverse Events. JAMA Dermatology, 2015, 151, 1392.	4.1	9
113	Quality of life in non-melanoma skin cancer. Australasian Journal of Dermatology, 2015, 56, 70-76.	0.7	56
114	Gemcitabine and vinorelbine treatment in cutaneous T-cell lymphoma in four patients. Australasian Journal of Dermatology, 2015, 56, 294-297.	0.7	2
115	Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. British Journal of Dermatology, 2015, 172, 239-243.	1.5	43
116	An analysis of the dermatological uses of mycophenolate mofetil in a tertiary hospital. Journal of Dermatological Treatment, 2015, 26, 63-66.	2.2	6
117	A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. New England Journal of Medicine, 2015, 373, 1618-1626.	27.0	469
118	Diffuse melanosis cutis in the setting of BRAF <sup>V600E</sup> mutant melanoma and treatment with targeted therapies. Australasian Journal of Dermatology, 2015, 56, 128-130.	0.7	5
119	Cutaneous non-tuberculous mycobacterial infection in patients with chronic graft-versus-host disease: A case series. Australasian Journal of Dermatology, 2015, 56, 124-127.	0.7	3
120	Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. JAMA Dermatology, 2015, 151, 1103.	4.1	139
121	Dermatology Over the Rainbow. JAMA Dermatology, 2015, 151, 543.	4.1	0
122	Phototherapy for the treatment of cutaneous graft versus host disease. Australasian Journal of Dermatology, 2015, 56, 93-99.	0.7	14
123	Localized cutaneous immunoglobulin G <sub>4</sub> . International Journal of Dermatology, 2015, 54, 955-958.	1.0	0
124	BRAF Inhibitor Induced Verrucal Keratosis. American Journal of Dermatopathology, 2014, 36, 192.	0.6	8
125	Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib. Australasian Journal of Dermatology, 2014, 55, 250-254.	0.7	60
126	Panniculitis in Patients Treated With BRAF Inhibitors. American Journal of Dermatopathology, 2014, 36, 493-497.	0.6	52



#	ARTICLE	IF	CITATIONS
127	Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy. <i>Melanoma Research</i> , 2014, 24, 501-503.	1.2	11
128	Dabrafenib-associated necrobiotic granulomatous reaction. <i>Australasian Journal of Dermatology</i> , 2014, 55, 306-308.	0.7	8
129	Behaviour, attitudes and awareness concerning sun exposure in adolescents on the Costa del sol. <i>European Journal of Dermatology</i> , 2014, 24, 85-93.	0.6	22
130	Deposits of Amyloid (Beta-2 Microglobulin Type) in the Tongue. <i>American Journal of Dermatopathology</i> , 2014, 36, 192-193.	0.6	0
131	Rational use of topical corticosteroids. <i>Australian Prescriber</i> , 2014, 37, 5-6.	1.0	0
132	Cutaneous toxicities of RAF inhibitors. <i>Lancet Oncology</i> , The, 2013, 14, e11-e18.	10.7	190
133	Non-evolving linear facial plaque. <i>Clinical and Experimental Dermatology</i> , 2013, 38, 681-683.	1.3	0
134	Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. <i>British Journal of Dermatology</i> , 2013, 169, 1310-1313.	1.5	41
135	Rational use of topical corticosteroids. <i>Australian Prescriber</i> , 2013, 36, 159-161.	1.0	12
136	Systemic Retinoid Therapy for Chemoprevention of Nonmelanoma Skin Cancer in a Patient Treated With Vemurafenib. <i>Journal of Clinical Oncology</i> , 2012, 30, e165-e167.	1.6	29
137	Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 569-572.	3.3	53
138	Erythema ab igne as a differential diagnosis of chronic graft versus host disease (GVHD). <i>International Journal of Dermatology</i> , 2012, 51, 1226-1227.	1.0	3
139	Lack of efficacy of rituximab in refractory sclerodermatous chronic GVHD. <i>Bone Marrow Transplantation</i> , 2012, 47, 737-738.	2.4	3
140	Bed Bugs: Clinical Relevance and Control Options. <i>Clinical Microbiology Reviews</i> , 2012, 25, 164-192.	13.6	272
141	Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis. <i>British Journal of Dermatology</i> , 2012, 166, 884-887.	1.5	50
142	Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. <i>British Journal of Dermatology</i> , 2012, 167, 1153-1160.	1.5	163
143	Lichen Planus-Like Drug Eruptions Due to $\beta_2$ -Blockers. <i>American Journal of Clinical Dermatology</i> , 2012, 13, 417-421.	6.7	22
144	Laptop dermatitis. <i>Medical Journal of Australia</i> , 2011, 194, 371-371.	1.7	0

#	ARTICLE	IF	CITATIONS
145	Sarcoidosis, Hypercalcemia and Calcium-sensing Receptor Mutation: A Case Report. Acta Dermato-Venereologica, 2011, 91, 468-468.	1.3	0
146	Many faces of graft-versus-host disease. Australasian Journal of Dermatology, 2010, 51, 1-10.	0.7	46
147	Squamous cell carcinoma arising in a recent plaque of discoid lupus erythematosus, in a sun-protected area. Lupus, 2010, 19, 210-212.	1.6	15
148	Potent topical steroids are one of the treatments for cutaneous T-cell lymphoma. Journal of Allergy and Clinical Immunology, 2010, 126, 414.	2.9	1
149	Cutaneous epithelioid angiosarcoma occurring at a peristomal site. Journal of the American Academy of Dermatology, 2010, 63, e55-e56.	1.2	7
150	Mohs micrographic surgery at the Skin and Cancer Foundation Australia, 10 years later (1997 vs 2007). Journal of the American Academy of Dermatology, 2010, 63, 832-835.	1.2	16
151	Array-CGH Reveals Recurrent Genomic Changes in Merkel Cell Carcinoma Including Amplification of L-Myc. Journal of Investigative Dermatology, 2009, 129, 1547-1555.	0.7	113
152	Stage IV cutaneous acute graft-versus-host disease. Clinical and histological study of 15 cases. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1398-1404.	2.4	12
153	Pachyonychia congenita and hidradenitis suppurativa: no response to infliximab therapy. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 1500-1501.	2.4	17
154	Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. Journal of the American Academy of Dermatology, 2008, 58, 375-381.	1.2	785
155	Las cabinas de bronceado, el cáncer de piel, los estándares internacionales y la función social del dermatólogo. Actas Dermo-sifiliográficas, 2008, 99, 429-430.	0.4	1
156	Self-Reported Adherence to Treatment and Quality of Life in Mild to Moderate Acne. Dermatology, 2008, 217, 309-314.	2.1	43
157	Cutaneous lichenoid graft-versus-host disease mimicking lupus erythematosus. Lupus, 2008, 17, 591-595.	1.6	16
158	Use of Biological Agents in Patients With Moderate to Severe Psoriasis. Archives of Dermatology, 2007, 143, 846-50.	1.4	18
159	Hidradenitis Suppurativa. Response to Treatment With Infliximab. Actas Dermo-sifiliográficas, 2007, 98, 325-331.	0.4	6
160	Stellate hypopigmented macules and papules on photoexposed areas. Clinical and Experimental Dermatology, 2007, 32, 337-338.	1.3	2
161	Quality of life in mild to moderate acne: relationship to clinical severity and factors influencing change with treatment. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 219-226.	2.4	66
162	Eosinophilic folliculitis following allogeneic peripheral blood stem cell transplantation: case report and review. Journal of Cutaneous Pathology, 2007, 34, 33-36.	1.3	19

#	ARTICLE	IF	CITATIONS
163	Alopecia syphilitica with detection of Treponema pallidum in the hair follicle. Journal of Cutaneous Pathology, 2007, 34, 37-40.	1.3	45
164	A <i>Polypodium leucotomos</i> extract inhibits solar-simulated radiation-induced TNF- $\alpha$ and iNOS expression, transcriptional activation and apoptosis. Experimental Dermatology, 2007, 16, 823-829.	2.9	56
165	The clinical and histologic spectrum of chronic graft-versus-host disease. Journal of the American Academy of Dermatology, 2006, 55, 729.	1.2	12
166	Implication of MT1-MMP in the maturation steps of benign melanocytic nevi. Journal of Cutaneous Pathology, 2006, 33, 139-144.	1.3	4
167	O'Brien actinic granuloma presenting as alopecia. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 226-227.	2.4	8
168	Acute severe form of lichenoid graft-versus-host disease after donor lymphocyte infusions. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 632-634.	2.4	4
169	Sentinel Lymph Node Biopsy for Evaluation and Treatment of Patients With Merkel Cell Carcinoma. Archives of Dermatology, 2006, 142, 685-90.	1.4	333
170	Atypical Early Follicular Graft-vs-Host Disease. Archives of Dermatology, 2006, 142, 1231.	1.4	7
171	A severe case of pachyonychia congenita type I due to a novel proline mutation in keratin 6a. British Journal of Dermatology, 2005, 152, 800-802.	1.5	6
172	Solar-Simulated Ultraviolet Radiation Induces Abnormal Maturation and Defective Chemotaxis of Dendritic Cells. Journal of Investigative Dermatology, 2005, 125, 334-342.	0.7	29
173	Role of Tetraspanins CD9 and CD151 in Primary Melanocyte Motility. Journal of Investigative Dermatology, 2005, 125, 1001-1009.	0.7	46
174	Maculopapular eruption with enlarged macrophages in eight patients receiving G-CSF or GM-CSF. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 310-313.	2.4	31
175	Dermatologic Treatment of Cutaneous Graft Versus Host Disease. American Journal of Clinical Dermatology, 2004, 5, 403-416.	6.7	37
176	Pustular acral erythema in a patient with acute graft-versus-host disease. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 550-553.	2.4	15
177	Diagnostic and neural analysis of skin cancer (DANAOS). A multicentre study for collection and computer-aided analysis of data from pigmented skin lesions using digital dermoscopy. British Journal of Dermatology, 2003, 149, 801-809.	1.5	112
178	Perianal Lentiginosis: A Case of Localized Lentiginosis. Acta Dermato-Venereologica, 2003, 83, 379-380.	1.3	1
179	Sclerodermatous Graft-vs-Host Disease. Archives of Dermatology, 2002, 138, 924-34.	1.4	92
180	Tetraspanins are Localized at Motility-Related Structures and Involved in Normal Human Keratinocyte Wound Healing Migration. Journal of Investigative Dermatology, 2000, 114, 1126-1135.	0.7	98

#	ARTICLE	IF	CITATIONS
181	The Spanish version of Skindex®29. International Journal of Dermatology, 2000, 39, 907-912.	1.0	65
182	Association of Helicobacter pylori Infection With Psoriasis and Lichen Planus: Prevalence and Effect of Eradication Therapy. Archives of Dermatology, 2000, 136, 1275-1276.	1.4	38
183	Differential Expression of Activation Epitopes of $\alpha$ 1 Integrins in Psoriasis and Normal Skin. Journal of Investigative Dermatology, 1998, 111, 19-24.	0.7	29
184	A Follicular Lichenoid Eruption as Manifestation of Chronic Graft-vs-Host Disease. Acta Dermato-Venereologica, 1998, 78, 386-386.	1.3	11
185	D - Penicillamine-induced pemphigus foliaceus with autoantibodies to desmoglein-1 in a patient with mixed connective tissue disease. Journal of the American Academy of Dermatology, 1997, 37, 121-123.	1.2	25
186	Perforating granuloma annulare. International Journal of Dermatology, 1997, 36, 340-348.	1.0	70
187	Pseudoxanthoma elasticum-like papillary dermal elastolysis. A report of two cases and review of the literature.. Acta Dermato-Venereologica, 1997, 77, 43-45.	1.3	18
188	Leishmaniasis presenting as a dermatomyositis-like eruption in AIDS. Journal of the American Academy of Dermatology, 1996, 35, 316-319.	1.2	56
189	Condyloma-like lesions as the presenting sign of multiple Myeloma associated amyloidosis. British Journal of Dermatology, 1996, 135, 665-666.	1.5	8
190	Lichen amyloidosis and Human Immunodeficiency Virus Infection. Dermatology, 1995, 191, 56-58.	2.1	6
191	Reticular Erythematous Mucinosi s Associated with Human Immunodeficiency Virus Infection. Dermatology, 1995, 191, 157-160.	2.1	15
192	Recall phenomenon with the unusual presence of eccrine squamous syringometaplasia. British Journal of Dermatology, 1995, 133, 630-632.	1.5	23
193	Malignant melanoma appearing in a seborrheic keratosis. British Journal of Dermatology, 1995, 133, 1016-1018.	1.5	14
194	Cutaneous lesions as the first sign of disseminated mucormycosis.. Acta Dermato-Venereologica, 1995, 75, 166-167.	1.3	8
195	Treatment of mycosis fungoides with etretinate and low-dose interferon $\alpha$ 2a. Journal of the European Academy of Dermatology and Venereology, 1994, 3, 326-330.	2.4	0
196	Cutaneous T-cell lymphoma and myelodysplastic syndrome. Journal of the American Academy of Dermatology, 1994, 31, 1065-1067.	1.2	4
197	Keratosis punctata of the Palmar Creases: Case Report and Prevalence Study in Caucasians. Dermatology, 1994, 188, 200-202.	2.1	18
198	Cutaneous meningioma underlying congenital localized hypertrichosis. Journal of the American Academy of Dermatology, 1994, 30, 363-366.	1.2	29

#	ARTICLE	IF	CITATIONS
199	Mechanism of mannose toxicity. Biochemical and Biophysical Research Communications, 1986, 140, 51-55.	2.1	48
200	Supine dermoscopy for improved visualisation of lower limb lesions. Dermatology Practical and Conceptual, 0, , e2022065.	0.9	0